Analysts Set Expectations for Legend Biotech FY2025 Earnings

Legend Biotech Co. (NASDAQ:LEGN) – Analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for Legend Biotech in a research report issued to clients and investors on Tuesday, January 21st. Cantor Fitzgerald analyst R. Bienkowski anticipates that the company will post earnings of ($0.72) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $83.00 price objective on the stock. The consensus estimate for Legend Biotech’s current full-year earnings is ($1.24) per share.

Legend Biotech (NASDAQ:LEGN) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.56) by $0.22. Legend Biotech had a negative net margin of 66.92% and a negative return on equity of 29.69%. The firm had revenue of $160.20 million for the quarter, compared to the consensus estimate of $143.91 million. During the same period in the previous year, the company earned ($0.17) earnings per share. The company’s quarterly revenue was up 66.9% on a year-over-year basis.

A number of other equities research analysts have also recently issued reports on the stock. HC Wainwright reissued a “buy” rating and issued a $73.00 target price on shares of Legend Biotech in a research report on Tuesday. Redburn Atlantic began coverage on shares of Legend Biotech in a research report on Tuesday, October 8th. They set a “buy” rating and a $86.00 price objective for the company. Piper Sandler reaffirmed an “overweight” rating and set a $78.00 price objective on shares of Legend Biotech in a research report on Monday, December 30th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $86.00 price objective on shares of Legend Biotech in a research report on Monday, December 9th. Thirteen research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $80.62.

Legend Biotech Trading Up 8.0 %

Shares of Legend Biotech stock opened at $37.44 on Wednesday. The firm has a 50-day moving average of $36.48 and a 200-day moving average of $45.83. The stock has a market cap of $6.84 billion, a PE ratio of -39.41 and a beta of 0.16. Legend Biotech has a 52-week low of $30.17 and a 52-week high of $70.13. The company has a debt-to-equity ratio of 0.27, a quick ratio of 4.90 and a current ratio of 4.98.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. FMR LLC increased its stake in shares of Legend Biotech by 4.0% in the third quarter. FMR LLC now owns 18,330,219 shares of the company’s stock valued at $893,232,000 after buying an additional 708,620 shares during the period. Westfield Capital Management Co. LP increased its position in Legend Biotech by 5.6% during the 3rd quarter. Westfield Capital Management Co. LP now owns 5,038,505 shares of the company’s stock valued at $245,526,000 after purchasing an additional 266,296 shares during the period. Massachusetts Financial Services Co. MA increased its position in Legend Biotech by 16.0% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 2,275,158 shares of the company’s stock valued at $110,868,000 after purchasing an additional 314,449 shares during the period. Matthews International Capital Management LLC increased its position in Legend Biotech by 14.9% during the 4th quarter. Matthews International Capital Management LLC now owns 1,185,516 shares of the company’s stock valued at $38,577,000 after purchasing an additional 153,665 shares during the period. Finally, State Street Corp increased its position in Legend Biotech by 0.4% during the 3rd quarter. State Street Corp now owns 1,140,222 shares of the company’s stock valued at $55,563,000 after purchasing an additional 4,735 shares during the period. Institutional investors and hedge funds own 70.89% of the company’s stock.

Legend Biotech Company Profile

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM).